Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

J Clin Endocrinol Metab 2006 Aug 9;91(8):2892-9. Epub 2006 May 9.

Institut Gustave Roussy, 94805 Villejuif CĂ©dex, France.

Aim: The goal of this study was to estimate the cumulative activity of (131)I to be administered to patients with distant metastases from thyroid carcinoma.

Methods: A total of 444 patients were treated from 1953-1994 for distant metastases from papillary and follicular thyroid carcinoma: 223 had lung metastases only, 115 had bone metastases only, 82 had both lung and bone metastases, and 24 had metastases at other sites. Treatment consisted of the administration of 3.7 GBq (100 mCi) (131)I after withdrawal of thyroid hormone treatment, every 3-9 months during the first 2 yr and then once a year until the disappearance of any metastatic uptake. Thyroxine treatment was given at suppressive doses between (131)I treatment courses.

Results: Negative imaging studies (negative total body (131)I scans and conventional radiographs) were attained in 43% of the 295 patients with (131)I uptake; more frequently in those who were younger, had well-differentiated tumors, and had a limited extent of disease. Most negative studies (96%) were obtained after the administration of 3.7-22 GBq (100-600 mCi). Almost half of negative studies were obtained more than 5 yr after the initiation of the treatment of metastases. Among patients who achieved a negative study, only 7% experienced a subsequent tumor recurrence. Overall survival at 10 yr after initiation of (131)I treatment was 92% in patients who achieved a negative study and 19% in those who did not.

Conclusion: (131)I treatment is highly effective in younger patients with (131)I uptake and with small metastases. They should be treated until the disappearance of any uptake or until a cumulative activity of 22 GBq has been administered. In the other patients, other treatment modalities should be used when tumor progression has been documented.

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2005-2838DOI Listing
August 2006
3 Reads

Publication Analysis

Top Keywords

distant metastases
12
131i treatment
12
metastases
9
administered patients
8
131i uptake
8
patients 131i
8
follicular thyroid
8
bone metastases
8
treatment
8
cumulative activity
8
negative studies
8
131i
8
papillary follicular
8
thyroid carcinoma
8
achieved negative
8
patients distant
8
444 patients
8
patients
8
negative study
8
metastases papillary
8

References

(Supplied by CrossRef)
Non toxic goiter and thyroid neoplasia
Schlumberger et al.
In: Larsen RP, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams’ textbook of endocrinology. 10th ed. Philadelphia: WB Saunders Company; 2003
The evolving role of 131I for the treatment of differentiated thyroid carcinoma
Robbins et al.
J Nucl Med 2005
Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma
Schlumberger et al.
J Nucl Med 1996
Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables
Casara et al.
J Nucl Med 1993
Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades
Dinneen et al.
J Clin Endocrinol Metab 1995

Similar Publications